O B E S I T Y / L I P I D S
Diabetes and Cardiovascular Disease When it comes to lipids, statins are all you need RAFAEL BITZUR,
MD
THE PREVALENCE OF DIABETES AND CARDIOVASCULAR DISEASE MORTALITY—The prevalence of obesity and diabetes continues to increase rapidly in the U.S. and all over the world (1–3). Obesity and diabetes are major risk factors for cardiovascular diseases (CVDs), but despite the increase in their prevalence, there seems to be a continuous steady decline in death rates from coronary heart disease (CHD) and stroke (4). Moreover, cause-specific excess death associated with obesity has been declining despite the increase in obesity rates (5). The reason behind this apparent paradox is probably a better control of other risk factors for CVD, such as cholesterol levels, hypertension, and smoking. Several trials demonstrated that more than half the decline in deaths from CHD in the last decades may be attributable to reductions in major risk factors (6). Of all risk factors, treating high cholesterol levels had the highest impact on the decline in CHD mortality (7). This is hardly surprising because the LDL cholesterol level is the strongest determinant of CHD risk, even in diabetic patients (8). Prevention of CHD in diabetic patients and the question of residual risk Statins are the most effective agents in reducing the risk of CHD in diabetic patients, reducing the relative risk by about one-third (9,10). An analysis based on the UK Prospective Diabetes Study (UKPDS) risk engine demonstrated that even in the Steno-2 study, in which
multifactorial intervention was used for the treatment of diabetes with an impressive reduction of both cardiovascular morbidity and mortality, lipid-lowering therapy accounted for more than 70% of CVD risk reduction (11). Actually, many more patients in the intensive therapy group achieved their cholesterol goal compared with the conventional therapy group (70 vs. 20%), while there was no difference between the groups in the attainment of their triglyceride goal (11). The main difference between the intensive and conventional treatment groups was in the use of statins (12). Eighty-five percent of the patients assigned to intensive therapy were given statins, compared with 22% of the patients assigned to conventional therapy. The result was a mean LDL cholesterol level of 83 mg/dL in the patients assigned to intensive therapy compared with 126 mg/dL in the patients assigned to conventional therapy (12). However, in all studies, the risk in the group assigned to intensive therapy remained high. The remaining large residual risk is often cited as a proof for statins not being efficient enough in reducing cardiovascular risk, and therefore for the need to combine statins with other lipidmodifying agents (13). A closer look at the data may offer a different explanation. The intensity of statin treatment. Current guidelines recommend a goal for LDL cholesterol of below 100 mg/dL, with a level of below 70 mg/dL as an optional goal, especially in individuals with diabetes and overt CVD (14). In real life, the mean LDL cholesterol level in patients
c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c
From The Bert W. Strassburger Lipid Center, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel. Corresponding author: Rafael Bitzur,
[email protected]. This publication is based on the presentations at the 3rd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy). The Congress and the publication of this supplement were made possible in part by unrestricted educational grants from AstraZeneca, Boehringer Ingelheim, BristolMyers Squibb, Daiichi Sankyo, Eli Lilly, Ethicon Endo-Surgery, Generex Biotechnology, F. Hoffmann-La Roche, Janssen-Cilag, Johnson & Johnson, Novo Nordisk, Medtronic, and Pfizer. DOI: 10.2337/dc11-s256 © 2011 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/ licenses/by-nc-nd/3.0/ for details.
S380
DIABETES CARE, VOLUME 34, SUPPLEMENT 2, MAY 2011
with diabetes is often higher than 100 mg/dL (15). Even in the controlled setting of statin trials, the mean LDL cholesterol level achieved in patients with diabetes is about 90 mg/dL (16). But even current goals may not be optimal for high-risk patients. The association between LDL cholesterol levels and CHD risk seemingly remains log linear at very low LDL cholesterol levels (17). In studies like PROVE-IT (Pravastatin or Atorvastatin Evaluation and Infection Therapy) and JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin), high-risk patients achieving LDL cholesterol levels below 40–50 mg/dL had a lower risk for cardiovascular events than patients failing to achieve such low levels (18,19). This may mean that use of high doses of potent statins in high-risk patients, such as those with diabetes, attaining LDL cholesterol levels below 40–50 mg/dL, may further reduce cardiovascular risk. It should be noted that although statins are relatively safe even when given in high doses, high doses of statins may cause muscle cramps in some patients. The timing of statin treatment. Current guidelines do not consider prediabetic patients to be at high risk of CVD in terms of recommended LDL cholesterol goals. However, prediabetic subjects have an atherogenic pattern of risk factors that may be present for many years and may contribute to the risk of CVD as much as the duration of clinical diabetes itself (20). In the Nurses’ Health Study, a significantly elevated risk of CVD was found before clinical diagnosis of type 2 diabetes (21). Among women who developed type 2 diabetes during follow-up, the ageadjusted relative risks of myocardial infarction were 3.75 (95% CI 3.10–4.53) for the period before the diagnosis and 4.57 (3.87–5.39) for the period after the diagnosis, compared with women who remained free of diabetes. In the DECODE (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe) study, patients with impaired glucose tolerance had lower survival rates than those with normal glucose tolerance. Participants with impaired fasting glucose had cumulative mortality curves similar care.diabetesjournals.org
Bitzur to but worse than those for normoglycemic individuals (22). In the AusDiab (Australian Diabetes, Obesity and Lifestyle) study, compared with those with normal glucose tolerance, the risk of death was increased in those with impaired fasting glucose (hazard ratio 1.6 [95% CI 1.0– 2.4]) and impaired glucose tolerance (1.5 [1.1–2.0]) (23). Long-term follow-up of patients participating in statin trials have demonstrated that the benefit of early statin therapy in high-risk patients that accrued during the double-blind trial period persisted during follow-up, despite a high rate of statin use in both groups after the trial. It seems that the full benefit cannot be achieved by starting treatment 5 years later (24,25). In the JUPITER study, none of the patients had diabetes, but many of the patients had the metabolic syndrome or other prediabetic states (19,26). These patients, treated with a high-dose potent statin, had a remarkable 45% decrease in the risk for cardiovascular events (19). However, even in JUPITER there was a 55% residual risk for CVD. This might be because patients in JUPITER were relatively old (mean age 66 years), as in most statin trials (19). There are no studies of statin therapy in young people, but there is a good example of naturally occurring low LDL cholesterol levels from a very young age. In the ARIC (Atherosclerosis Risk in Communities) trial, naturally occurring low LDL cholesterol levels from birth because of mutations and sequence variants in the gene for PCSK9 were associated with an up to 88% reduction in the risk for cardiovascular events (27). Therefore, it seems logical to start statin therapy in prediabetic patients. Such early therapy may reduce risk even further. Drug treatment of other components of dyslipidemia and the risk for CVD There have been many attempts to find drugs that would improve triglyceride and HDL cholesterol levels and confer additional benefit when given on top of statins. So far, all have failed. Although fibrates have been shown to reduce cardiovascular risk in some studies such as VA-HIT (Veterans Affairs High-Density Lipoprotein Intervention Trial) (28), their value, when added to statins, have never been proved. Fenofibrate did not reduce morbidity and mortality in diabetic patients in the FIELD (Fenofibrate Intervention and care.diabetesjournals.org
Event Lowering in Diabetes) and ACCORD (Action to Control Cardiovascular Risk in Diabetes) trials (29,30). Torcetrapib increased the risks of mortality and morbidity despite increasing HDL cholesterol levels (31). Omega-3 fatty acids were never tested for their ability to decrease morbidity and mortality when used as antilipidemic agents. Niacin decreased morbidity and mortality when used alone in postmyocardial infarction patients (32), but the results of studies testing its effect when given on top of statins are still pending. Moreover, because niacin reduces LDL cholesterol levels as well as increases HDL cholesterol and decreases triglyceride levels, any potential beneficial effects of this drug may be because of its LDL cholesterol–lowering effect. Many other drugs have either failed to reduce cardiovascular morbidity and mortality despite improving HDL cholesterol levels (e.g., roziglitazone, hormone replacement therapy) or even caused harm (e.g., rimonabant, muraglitazar). In fact, a recent systematic review looking at the association between treatmentinduced change in HDL cholesterol and cardiovascular morbidity and mortality change in HDL cholesterol explained almost no variability in any of the outcomes. Reduction in LDL cholesterol levels, on the other hand, was associated with reduction in morbidity and mortality (33). CONCLUSIONS—LDL cholesterol is the major risk factor for cardiovascular complications in diabetic patients. Statins significantly reduce cardiovascular risk in diabetic patients. Starting statin therapy before diabetes develops and treating to lower LDL cholesterol targets than is currently recommended may reduce risk even further. There is no evidence that other antilipidemic agents improve clinical outcomes.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
Acknowledgments—No potential conflicts of interest relevant to this article were reported. 14. References 1. Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the U.S.: 1990-1998. Diabetes Care 2000;23:1278–1283 2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047– 1053 3. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in
15.
16.
obesity among US adults, 1999-2000. JAMA 2002;288:1723–1727 National Heart, Lung, and Blood Institute. The morbidity and mortality: chart book on cardiovascular, lung, and blood diseases [Internet], 2009. Available from http:// www.nhlbi.nih.gov/resources/docs/2009_ ChartBook.pdf. Accessed 1 April 2011 Flegal KM, Graubard BI, Williamson DF, Gail MH. Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA 2007;298:2028–2037 Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 2007;356:2388–2398 Laatikainen T, Critchley J, Vartiainen E, Salomaa V, Ketonen M, Capewell S. Explaining the decline in coronary heart disease mortality in Finland between 1982 and 1997. Am J Epidemiol 2005;162: 764–773 Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in noninsulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316:823–828 Colhoun HM, Betteridge DJ, Durrington PN, et al.; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebocontrolled trial. Lancet 2004;364:685– 696 Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005–2016 Gaede P, Pedersen O. Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis (Abstract). Diabetes 2004;53(Suppl. 3):S39–S47 Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580–591 Polonsky TS, Davidson MH. Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy (Abstract). Am J Cardiol 2008;101:27B–35B American Diabetes Association. Standards of medical care in diabetes—2010 (Position Statement). Diabetes Care 2010;33 (Suppl. 1):S11–S61 Preis SR, Pencina MJ, Hwang SJ, et al. Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study. Circulation 2009;120:212–220 Kearney PM, Blackwell L, Collins R, et al.; Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in
DIABETES CARE, VOLUME 34, SUPPLEMENT 2, MAY 2011
S381
Diabetes and cardiovascular disease
17.
18.
19.
20.
21.
14 randomised trials of statins: a metaanalysis. Lancet 2008;371:117–125 Grundy SM, Cleeman JI, Merz CN, et al.; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 2004;44:720–732 Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E; PROVE IT-TIMI 22 Investigators. Can lowdensity lipoprotein be too low? The safety and efficacy of achieving very low lowdensity lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005;46:1411–1416 Ridker PM, Danielson E, Fonseca FAH, et al.; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195–2207 Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990;263: 2893–2898 Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002;25:1129–1134
S382
22. The DECODE study group; European Diabetes Epidmiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet 1999;354:617– 621 23. Barr EL, Zimmet PZ, Welborn TA, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007;116:151–157 24. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM; West of Scotland Coronary Prevention Study Group. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007;357:1477–1486 25. Strandberg TE, Pyörälä K, Cook TJ, et al.; 4S Group. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004;364:771–777 26. Kappagoda CT, Amsterdam EA. Another look at the results of the JUPITER trial. Am J Cardiol 2009;104:1603–1605 27. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354: 1264–1272
DIABETES CARE, VOLUME 34, SUPPLEMENT 2, MAY 2011
28. Rubins HB, Robins SJ, Collins D, et al.; Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410–418 29. Keech A, Simes RJ, Barter P, et al.; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849– 1861 30. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362: 1563–1574 31. Barter PJ, Caulfield M, Eriksson M, et al.; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357: 2109–2122 32. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245– 1255 33. Briel M, Ferreira-Gonzalez I, You JJ, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and metaregression analysis. BMJ 2009;338:b92
care.diabetesjournals.org
